CTD Holdings Engages Torreya Capital as Strategic Advisor
13 nov. 2018 08h43 HE
|
CTD Holdings, Inc.
ALACHUA, Fla., Nov. 13, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with...
CTD Announces Partnership with Synteract to support the Extension Protocol for its Phase I Clinical Trial in the United States
08 nov. 2018 15h07 HE
|
CTD Holdings, Inc.
ALACHUA, Fla., Nov. 08, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with...
CTD Holdings Announces Filing of Patent Application for Use of Hydroxypropyl Beta Cyclodextrins in the Treatment of Alzheimer’s Disease
29 oct. 2018 18h49 HE
|
CTD Holdings, Inc.
ALACHUA, Fla., Oct. 29, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with...
CTD Holdings Posts Recording of its Webinar on US Clinical Trial
18 oct. 2018 16h31 HE
|
CTD Holdings, Inc.
Webinar recording is on the Company website ALACHUA, Fla., Oct. 18, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops...
CTD Holdings Announces Plans to Broaden its Expanded Access Program for Trappsol® Cyclo™
15 oct. 2018 08h00 HE
|
CTD Holdings, Inc.
Company expects to provide its drug to new patients in early 2019 ALACHUA, Fla., Oct. 15, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that...
CTD Holdings to Host Webinar on its Phase I Clinical Trial for Niemann-Pick Disease Type C
11 oct. 2018 12h57 HE
|
CTD Holdings, Inc.
ALACHUA, Fla., Oct. 11, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of...
CTD Holdings to Present at BioFlorida Conference with update on Clinical Program Using Cyclodextrins to treat diseases with Unmet Medical Needs
09 oct. 2018 12h03 HE
|
CTD Holdings, Inc.
ALACHUA, Fla., Oct. 09, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biopharmaceutical company that develops cyclodextrin-based products for the treatment of disease...
CTD Holdings Establishes Second Clinical Trial Site for US Phase I Clinical Study of Trappsol® Cyclo™ for Treatment of Niemann-Pick Disease Type C
05 oct. 2018 08h00 HE
|
CTD Holdings, Inc.
Patients to be Enrolled at Atlantic Health System’s Morristown Medical Center, Morristown, New Jersey ALACHUA, Fla., Oct. 05, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical...
CTD announces encouraging top-line data from two ongoing clinical trials of Trappsol® Cyclo™ administered intravenously in Niemann Pick Disease Type C (NPC)
03 oct. 2018 08h00 HE
|
CTD Holdings, Inc.
ALACHUA, Fla., Oct. 03, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of...
CTD Holdings to Present at UK Annual Conference for NPC Patients, Families, and Health Professionals
13 sept. 2018 10h56 HE
|
CTD Holdings, Inc.
Conference Brings the NPC community together for scientific exchanges and information sharing with NPC families ALACHUA, Fla., Sept. 13, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH),...